Richard Faichney

Richard is a Senior Associate in the Corporate group and is part of the Corporate Technology team. He specialises in advising businesses, investors and founders in the technology, media and communication sector. He has a broad corporate practice including public and private M&A, joint ventures, fundraising and venture capital, governance and general corporate issues.

Show full CV Hide full CV

Career

Since 2019	Senior Associate, Taylor Wessing
2013 - 2019	Associate, Slaughter and May

Education

2012 - 2013	BPP School of Law, LPC
2011 - 2012	BPP School of Law, Graduate diploma in law
2007 - 2011	University of Edinburgh, Law

Expertise

Sectors Life sciences & healthcare Technology, media & communications Energy & infrastructure Gaming Fintech Biotech Digital health

Experience

Advising Jagex on its sale	Long-standing client Jagex, one of the UK’s largest video game developers and publishers, on its sale to The Carlyle Group. The transaction positions Jagex for continued growth in the global gaming market, building upon its existing 300 million players accounts and $1bn RuneScape franchise.
Nutmeg on its acquisition by JPMorgan Chase	Long-standing client Nutmeg Saving and Investment Limited, one of the UK’s leading digital wealth managers, on its sale to JPMorgan Chase. The acquisition positions Nutmeg, with over 140,000 investors and £3.5 billion AUM, as an integral part of the bank’s international offering and complements the launch of Chase as a digital bank in the UK.
Yoto on $17 million Series A fundraising for one of 2020's Best Inventions of the Year	Yoto, the audio platform for children, on its $17 million Series A fundraising to help facilitate its rapid growth across Europe and North America. The investment followed the successful launch in early 2020 of the 2nd generation Yoto Player, subsequently awarded one of TIME magazine’s Inventions of the Year.

Oppilan and Zomagen on their sale to Ventyx as part of concurrent $114 million crossover financing	Oppilan Pharma Limited and Zomagen Biosciences Limited on their roll-up and sale into Ventyx Biosciences, Inc. and concurrent $114 million crossover financing led by venBio Partners. The transaction brings together three cutting-edge life sciences companies to create a clinical-stage biotechnology company developing immune modulators to treat inflammatory diseases and autoimmune disorders. Investors included Third Point and RTW Investments.
Multiverse on its $44 million Series B fundraising	Multiverse (formerly known as WhiteHat), a UK start-up working with organisations to tackle skills gaps through apprenticeships, on its $44 million Series B funding round. The funding will be used to continue growth in the UK and spearhead a move into the US market. The round was led by General Catalyst, with among others Index Ventures, Lightspeed Venture Partners, and GV (formerly known as Google Ventures).
Babylon Health continues to invest in digital healthcare with largest European and US fundraising	Babylon Health, a UK-based digital health subscription provider, on its USD550m fundraising to support expansion into the US and Asia. This is the largest ever fundraising in the European or US digital health sector and values Babylon at over USD2bn. Investors included PIF, ERGO Fund, Kinnevik and Vostok New Ventures.